Merck Says Phase 3 KEYNOTE-756 Trial Met Primary Endpoint Of Pathological Complete Response (pCR) Rate In Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck announced that its Phase 3 KEYNOTE-756 trial met its primary endpoint of Pathological Complete Response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. This is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient population.
July 28, 2023 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's successful Phase 3 KEYNOTE-756 trial could potentially lead to a new treatment option for high-risk, early-stage ER+/HER2- breast cancer patients, which may positively impact the company's stock.
The successful trial results indicate that Merck is making significant progress in its cancer research, which could potentially lead to a new treatment option for high-risk, early-stage ER+/HER2- breast cancer patients. This could increase the company's market share in the cancer treatment market, leading to potential revenue growth and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100